• Nazli Haciagaoglu, Huseyin Cetin, Ozlem Hurmeydan, and Engin Ersin Simsek.
• Department of Family Medicine, University of Health Sciences, Kartal Dr. Lutfi Kırdar City Hospital, Turkey.
• J Coll Physicians Surg Pak. 2021 Feb 1; 31 (2): 177-181.

ObjectiveTo determine cardiovascular risk factors, calculate cardiovascular risk, and the value of betatrophin, a novel biomarker in predicting the risk of cardiovascular disease (CVD) in obese individuals.Study DesignCross-sectional and descriptive study.Place And Duration Of Study University of Health Sciences, Kartal Dr. Lutfi Kırdar City Hospital, Turkey, from August to November 2019.Methodology Three hundred and sixty-three patients sociodemographic information was obtained, anthropometric measurements were made, and routine laboratory examinations were taken for obesity. In addition, betatrophin was studied from the samples collected and stored under appropriate conditions. The risk of CVD development in the patients was calculated using Framingham and PRCAE risk calculation systems.ResultsThe median betatrophin level of the participants was 745.8 (636.3-935.7) ng/L. A significant relationship was found between Framingham sub-risk groups and betatrophin level (p=0.049). Moreover, a significant relationship was also found, especially between the medium-risk group and the high-risk group (p=0.029). A significant correlation was found between the triglyceride and the betatrophin levels (p=0.001, r=-0.166). No relation was found between betatrophin level and risk score in the PRCAE sub-risk groups.ConclusionIts significant relationship with the risk groups determined by the Framingham scoring system and triglyceride level is promising for betatrophin to be used as a new biomarker in predicting the CVD risk. Key Words: Betatrophin, Framingham score, Cardiovascular disease, Obesity, Risk.

19 keywords...

hide…